A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy with Clindamycin and Triamcinolone in Glioblastoma Patients Treated with Tumor Treating Fields (Brain Tumors)
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects
Sponsor: Novocure
Enrolling: Male and Female Patients
IRB Number: AAAT5146
U.S. Govt. ID: NCT04469075
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test whether using clindamycin and triamcinolone topical lotions canprevent skin-related side effects of tumor treating fields (TTFields). Clindamycin is an antibiotic. It works by slowing or stopping the growth of bacteria. The FDA has approved the drug for the treatment of various bacterial infections. However, giving clindamycin to people to prevent skin-related side effects of TTFields is an investigational use of the drug. The FDA has not approved this use. Triamcinolone is a corticosteroid. It works by copying the effects of hormones that your body makes naturally to prevent inflammation. The FDA has approved triamcinolone for the treatment of itching skin (pruritus) and several other skin conditions that are characterized by inflammation, such as eczema, psoriasis, or allergies. However, giving triamcinolone to people to prevent skin-related side effects of TTFields is an investigational use of the drug. The study drugs (clindamycin and triamcinolone) will be provided by Memorial Sloan Kettering Cancer Center (MSK).
This study is closed
Investigator
Fabio Iwamoto, MD
Do You Qualify?
Are you age 18 or older? Yes No
Do you have a new diagnosis of glioblastoma? Yes No
Are you able to apply topical drugs or do you have someone that can assist in applying topical drugs? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162